Agennix AG
Description Agennix AG, a biopharmaceutical company, focuses on the development of therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need primarily in Germany and the United States. The companys lead product candidate under development includes Talactoferrin, an oral dendritic cell mediated immunotherapy that has completed phase III trial enrollment for the treatment of non-small cell lung cancer; and phase II clinical trial for the treatment of severe sepsis. Its developmental stage products also include topical talactoferrin, which has completed phase IIa clinical trial for the treatment of diabetic foot ulcers; and RGB-286638, a multi-targeted kinase inhibitor that has completed phase I trial for the treatment of solid tumors. The company has manufacturing and supply agreement with DSM Capua S.p.A.; and manufacturing services agreement with Lonza Sales AG. Agennix AG is based in Heidelberg, Germany. To view the detailed information, you need to SUBSCRIBE with us. |
 |